5005 MCCONNELL AVE, LOS ANGELES, CA
Other Events
Financial Results, Press Release
Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Enters Credit Agreement Amendments Extending Maturity
Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals Enters $100 Million Capital on Demand Sales Agreement
Announces Third Quarter 2025 Results and Provides Corporate Update
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload